Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis.

Colado A, Genoula M, Cougoule C, Marín Franco JL, Almejún MB, Risnik D, Kviatcovsky D, Podaza E, Elías EE, Fuentes F, Maridonneau-Parini I, Bezares FR, Fernandez Grecco H, Cabrejo M, Jancic C, Sasiain MDC, Giordano M, Gamberale R, Balboa L, Borge M.

Blood Cancer J. 2018 Nov 5;8(11):100. doi: 10.1038/s41408-018-0136-x. No abstract available.

2.

Chronic lymphocytic leukemia cells increase neutrophils survival and promote their differentiation into CD16high CD62Ldim immunosuppressive subset.

Podaza E, Risnik D, Colado A, Elías E, Almejún MB, Fernandez Grecco H, Bezares RF, Borge M, Gamberale R, Giordano M.

Int J Cancer. 2019 Mar 1;144(5):1128-1134. doi: 10.1002/ijc.31762. Epub 2018 Sep 29.

PMID:
30178523
3.

Autologous T-cell activation fosters ABT-199 resistance in chronic lymphocytic leukemia: rationale for a combined therapy with SYK inhibitors and anti-CD20 monoclonal antibodies.

Elías EE, Almejún MB, Colado A, Cordini G, Vergara-Rubio M, Podaza E, Risnik D, Cabrejo M, Fernández-Grecco H, Bezares RF, Custidiano MDR, Sánchez-Ávalos JC, Vicente Á, Garate GM, Borge M, Giordano M, Gamberale R.

Haematologica. 2018 Oct;103(10):e458-e461. doi: 10.3324/haematol.2018.188680. Epub 2018 May 10. No abstract available.

4.

Revisiting the role of interleukin-8 in chronic lymphocytic leukemia.

Risnik D, Podaza E, Almejún MB, Colado A, Elías EE, Bezares RF, Fernández-Grecco H, Cranco S, Sánchez-Ávalos JC, Borge M, Gamberale R, Giordano M.

Sci Rep. 2017 Nov 16;7(1):15714. doi: 10.1038/s41598-017-15953-x.

5.

Sphingosine kinase 1 participates in the activation, proliferation and survival of chronic lymphocytic leukemia cells.

Almejún MB, Borge M, Colado A, Elías EE, Podaza E, Risnik D, De Brasi CD, Stanganelli C, Slavutsky I, Cabrejo M, Fernández-Grecco H, Bezares RF, Cranco S, Burgos RÁ, Sánchez-Ávalos JC, Oppezzo P, Giordano M, Gamberale R.

Haematologica. 2017 Jul;102(7):e257-e260. doi: 10.3324/haematol.2017.167353. Epub 2017 Mar 30. No abstract available.

6.

The kinase inhibitors R406 and GS-9973 impair T cell functions and macrophage-mediated anti-tumor activity of rituximab in chronic lymphocytic leukemia patients.

Colado A, Almejún MB, Podaza E, Risnik D, Stanganelli C, Elías EE, Dos Santos P, Slavutsky I, Fernández Grecco H, Cabrejo M, Bezares RF, Giordano M, Gamberale R, Borge M.

Cancer Immunol Immunother. 2017 Apr;66(4):461-473. doi: 10.1007/s00262-016-1946-y. Epub 2016 Dec 23.

PMID:
28011996
7.

Neutrophils from chronic lymphocytic leukemia patients exhibit an increased capacity to release extracellular traps (NETs).

Podaza E, Sabbione F, Risnik D, Borge M, Almejún MB, Colado A, Fernández-Grecco H, Cabrejo M, Bezares RF, Trevani A, Gamberale R, Giordano M.

Cancer Immunol Immunother. 2017 Jan;66(1):77-89. doi: 10.1007/s00262-016-1921-7. Epub 2016 Oct 28.

PMID:
27796477
8.

Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.

Borge M, Belén Almejún M, Podaza E, Colado A, Fernández Grecco H, Cabrejo M, Bezares RF, Giordano M, Gamberale R.

Haematologica. 2015 Apr;100(4):e140-2. doi: 10.3324/haematol.2014.119669. Epub 2015 Jan 23. No abstract available.

9.

The expression of sphingosine-1 phosphate receptor-1 in chronic lymphocytic leukemia cells is impaired by tumor microenvironmental signals and enhanced by piceatannol and R406.

Borge M, Remes Lenicov F, Nannini PR, de los Ríos Alicandú MM, Podaza E, Ceballos A, Fernández Grecco H, Cabrejo M, Bezares RF, Morande PE, Oppezzo P, Giordano M, Gamberale R.

J Immunol. 2014 Sep 15;193(6):3165-74. doi: 10.4049/jimmunol.1400547. Epub 2014 Aug 15.

Supplemental Content

Loading ...
Support Center